


STATUS OF THE CLAIMS

Claims 1 – 129. (canceled)

Claim 130 (previously presented). A benzodiazepine compound having the structure:



or its enantiomer,

wherein,

R1 is selected from the group consisting of an aliphatic group having at least 2 carbons, a substituted aliphatic group having at least 2 carbons, an aryl group, and a substituted aryl group;

and wherein R2 and R3 is independently selected from the group consisting of hydrogen, hydroxy, alkoxy, halo, amino, lower-alkyl-substituted-amino, acetylamino, hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, aryl, and heterocyclic;

wherein R4 is aliphatic, substituted aliphatic, aryl, substituted aryl, NH₂, or a group that participates in hydrogen bond formation;

or a pharmaceutically acceptable salt, prodrug or derivative thereof.

Claim 131. (previously presented) The compound of claim 130, wherein R2 is hydroxy.

Claim 132. (previously presented) The compound of claim 130, wherein R3 is a halogen.

Claim 133 (previously presented) The compound of claim 130, wherein R2 is hydroxy and R3 is a halogen.

Claim 134 (canceled).

Claim 135 (canceled).




Claim 136 (canceled).

Claim 137 (canceled).

Claim 138. (previously presented)

The compound of Claim 130, wherein R4 is

selected from the group consisting of



and

Claim 139. (previously presented)

The compound of Claim 130, wherein said

composition is a pharmaceutical composition.

Claim 140. (previously presented)

The compound of Claim 139, further

comprising a carrier.